20.95
price down icon5.46%   -1.21
after-market Dopo l'orario di chiusura: 21.10 0.15 +0.72%
loading
Precedente Chiudi:
$22.16
Aprire:
$22.021
Volume 24 ore:
2.88M
Relative Volume:
1.38
Capitalizzazione di mercato:
$2.11B
Reddito:
$352.57M
Utile/perdita netta:
$-143.01M
Rapporto P/E:
-11.57
EPS:
-1.81
Flusso di cassa netto:
$-153.40M
1 W Prestazione:
+2.44%
1M Prestazione:
+22.16%
6M Prestazione:
-19.36%
1 anno Prestazione:
-29.72%
Intervallo 1D:
Value
$20.83
$22.35
Intervallo di 1 settimana:
Value
$20.41
$22.80
Portata 52W:
Value
$13.53
$35.25

Beam Therapeutics Inc Stock (BEAM) Company Profile

Name
Nome
Beam Therapeutics Inc
Name
Telefono
857-327-8775
Name
Indirizzo
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Name
Dipendente
502
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-05
Name
Ultimi documenti SEC
Name
BEAM's Discussions on Twitter

Confronta BEAM con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
BEAM
Beam Therapeutics Inc
20.95 2.23B 352.57M -143.01M -153.40M -1.81
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-03-28 Aggiornamento BofA Securities Neutral → Buy
2025-03-10 Aggiornamento Scotiabank Sector Perform → Sector Outperform
2025-01-29 Aggiornamento Cantor Fitzgerald Neutral → Overweight
2024-11-06 Aggiornamento Leerink Partners Market Perform → Outperform
2024-10-16 Iniziato Scotiabank Sector Outperform
2024-07-23 Iniziato H.C. Wainwright Buy
2024-01-29 Aggiornamento JP Morgan Neutral → Overweight
2023-12-15 Downgrade BofA Securities Buy → Neutral
2023-12-08 Downgrade Jefferies Buy → Hold
2023-10-20 Downgrade Cantor Fitzgerald Overweight → Neutral
2023-10-20 Downgrade Leerink Partners Outperform → Market Perform
2023-03-21 Iniziato Bernstein Mkt Perform
2023-02-01 Iniziato Cantor Fitzgerald Overweight
2022-12-20 Aggiornamento BMO Capital Markets Market Perform → Outperform
2022-12-13 Iniziato Citigroup Buy
2022-06-17 Iniziato BMO Capital Markets Market Perform
2022-04-28 Iniziato Credit Suisse Neutral
2022-01-05 Iniziato Guggenheim Buy
2021-10-19 Iniziato SVB Leerink Outperform
2021-09-24 Ripresa Stifel Buy
2021-09-10 Iniziato BofA Securities Buy
2021-05-11 Iniziato Redburn Buy
2021-05-04 Iniziato RBC Capital Mkts Sector Perform
2021-03-01 Downgrade Barclays Overweight → Equal Weight
2021-02-16 Iniziato Wells Fargo Overweight
2021-01-29 Downgrade JP Morgan Overweight → Neutral
2021-01-06 Iniziato Stifel Hold
2020-08-05 Iniziato William Blair Outperform
2020-03-02 Iniziato Barclays Overweight
2020-03-02 Iniziato JP Morgan Overweight
2020-03-02 Iniziato Jefferies Buy
2020-03-02 Iniziato Wedbush Outperform
Mostra tutto

Beam Therapeutics Inc Borsa (BEAM) Ultime notizie

pulisher
Jul 24, 2025

Trading (BEAM) With Integrated Risk Controls - news.stocktradersdaily.com

Jul 24, 2025
pulisher
Jul 24, 2025

Can Beam Therapeutics Inc. stock recover from recent declineSky-high return potential - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

What institutions are buying Beam Therapeutics Inc. stock nowOutperformance with explosive growth - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 23, 2025

Beam Therapeutics Inc. Stock Analysis and ForecastFree Stock Movement Tracking - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

What drives Beam Therapeutics Inc. stock priceDynamic investment opportunities - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Beam Therapeutics Inc. stockFree High-Return Strategy Alerts - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Beam Therapeutics Inc. a good long term investmentRobust financial gains - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Sickle Cell Disease Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA - The Globe and Mail

Jul 21, 2025
pulisher
Jul 21, 2025

Beam Therapeutics (BEAM) Announces Acquisition of an Early-Stage Life Sciences Company - MSN

Jul 21, 2025
pulisher
Jul 16, 2025

12 Oversold NASDAQ Stocks to Buy Now - Insider Monkey

Jul 16, 2025
pulisher
Jul 14, 2025

(BEAM) Trading Report - news.stocktradersdaily.com

Jul 14, 2025
pulisher
Jul 13, 2025

Beam Therapeutics (BEAM) Surges 5.7%: Is This an Indication of Further Gains? - MSN

Jul 13, 2025
pulisher
Jul 08, 2025

H.C. Wainwright Reiterates a Buy Rating on Beam Therapeutics (BEAM) With an $80 PT - MSN

Jul 08, 2025
pulisher
Jul 07, 2025

Cathie Wood’s ARK ETF bolsters Beam stock, sheds Roblox - Investing.com

Jul 07, 2025
pulisher
Jul 06, 2025

Beam Therapeutics: A Base Editing Breakthrough With Catalysts to Ignite Value - AInvest

Jul 06, 2025
pulisher
Jul 04, 2025

Beam Therapeutics’ BEAM-101 Shows Promising Results in Sickle Cell Disease Trial - MSN

Jul 04, 2025
pulisher
Jul 04, 2025

Beam Therapeutics Acquires Early-Stage Life Sciences Firm - The Globe and Mail

Jul 04, 2025
pulisher
Jul 01, 2025

H.C. Wainwright reiterates Buy rating on Beam Therapeutics stock at $80 target - Investing.com

Jul 01, 2025
pulisher
Jun 30, 2025

Beam Therapeutics: A Contrarian Opportunity in Gene Editing Amid Russell Reconstitution - AInvest

Jun 30, 2025
pulisher
Jun 30, 2025

Top 10 CRISPR Stocks to Buy Now - Insider Monkey

Jun 30, 2025
pulisher
Jun 30, 2025

Beam Therapeutics Inc.(NasdaqGS: BEAM) dropped from Russell 3000 Value Index - MarketScreener

Jun 30, 2025
pulisher
Jun 27, 2025

3 Promising Genomics Stocks to Keep an Eye On in 2025 - The Globe and Mail

Jun 27, 2025
pulisher
Jun 24, 2025

BEAM-101 shows sustained benefits as treatment for sickle cell - Sickle Cell Disease News

Jun 24, 2025
pulisher
Jun 20, 2025

Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases - Seeking Alpha

Jun 20, 2025
pulisher
Jun 19, 2025

Can Casgevy Deliver a Turnaround for CRISPR Therapeutics? - Yahoo Finance

Jun 19, 2025
pulisher
Jun 18, 2025

Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Benzinga

Jun 18, 2025
pulisher
Jun 18, 2025

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - Yahoo Finance

Jun 18, 2025
pulisher
Jun 17, 2025

Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - The Motley Fool

Jun 17, 2025
pulisher
Jun 17, 2025

BEAM Therapeutics’ SWOT analysis: base editing pioneer’s stock faces pivotal year - Investing.com

Jun 17, 2025
pulisher
Jun 16, 2025

H.C. Wainwright reiterates buy rating on Beam Therapeutics stock By Investing.com - Investing.com Nigeria

Jun 16, 2025
pulisher
Jun 16, 2025

H.C. Wainwright reiterates buy rating on Beam Therapeutics stock - Investing.com

Jun 16, 2025
pulisher
Jun 14, 2025

Cathie Wood’s ARK ETFs adjust holdings, buying GitLab and Beam Therapeutics stock - Investing.com Nigeria

Jun 14, 2025

Beam Therapeutics Inc Azioni (BEAM) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Capitalizzazione:     |  Volume (24 ore):